Senate health committee Chair Bernie Sanders (I-VT) and Rep. Lloyd Doggett (D-TX) are among those concerned about the price tag of the Biden administration’s move to allow Medicare and Medicaid to cover GLP-1 drugs for obesity, celebrating the move forward for patient access but pushing for more action to lower the drugs’ prices. Drug price control group Public Citizen, meanwhile, said the federal government should deflate GLP-1 prices by allowing generic competition. “We cannot allow Medicare and Medicaid to simply...